Pathos AI at a glance
As of- [1] Latest valuation: SiliconANGLE, October 23, 2026
- [2] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), October 23, 2026
- [3] Lead investors: SiliconANGLE, October 23, 2026
Is this your company? Get featured or correct your listing →
Recent changes
- Oct 23, 2026Oct 23, 2026Raised $237M Series E at a $3B valuation SiliconANGLE
- Oct 23, 2026Oct 23, 2026First reported valuation: $3B SiliconANGLE
- Oct 23, 2026Oct 23, 2026New investor: Bristol Myers Squibb SiliconANGLE
- Oct 23, 2026Oct 23, 2026New investor: New Enterprise Associates (NEA) SiliconANGLE
- Oct 23, 2026Oct 23, 2026New investor: General Atlantic SiliconANGLE
Earlier changes (1)
- Oct 23, 2026Oct 23, 2026Pathos AI Hits $3B Valuation In $237M Round Led By BMS Pulse story
Funding history
1 equity event · newest first · sources dated per row| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Oct 23, 2026 | Series E | $237M | $3Bpost-money | Bristol Myers Squibbunverified | SiliconANGLE |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Investors
Latest Pulse
- Oct 25, 2026Zai Lab's $250M PIPE Shows How Biotechs Refill PipelinesNasdaq-listed Zai Lab raised about $250 million in a PIPE financing, selling 11.34 million shares at $22.04 each to fund its DLL3-targeting cancer drug, a reminder that public biotechs still lean on private placements between launches.→
- Oct 25, 2026Why Big Pharma Is Co-Leading AI Biotech Rounds NowBristol Myers Squibb led Pathos AI's $237M Series E and OrbiMed and Janus Henderson co-led Star Therapeutics' $200M round this week, a shift from pharma acquiring AI biotechs to funding them directly.→
- Oct 25, 2026Biotech's AI Bet: $687M Across Three Rounds In One WeekThree biotech financings announced in the same week pushed $687 million into AI-linked drug development, with OrbiMed and Janus Henderson among the investors doubling down on the sector.→
- Oct 23, 2026Pathos AI Hits $3B Valuation In $237M Round Led By BMSPathos AI raised $237 million in a Series E led by Bristol Myers Squibb at a $3 billion valuation, as Big Pharma deepens its direct bet on AI-designed cancer drugs.→
Coverage Timeline
newest firstAll Coverage
FUNDING$437M Combined
Why Big Pharma Is Co-Leading AI Biotech Rounds Now
Bristol Myers Squibb led Pathos AI's $237M Series E and OrbiMed and Janus Henderson co-led Star Therapeutics' $200M round this week, a shift from pharma acquiring AI biotechs to funding them directly.
DEEP DIVE
Pathos AI Hits $3B Valuation In $237M Round Led By BMS
FUNDING$237M Series E
Pathos AI Hits $3B Valuation In $237M Round Led By BMS
Pathos AI raised $237 million in a Series E led by Bristol Myers Squibb at a $3 billion valuation, as Big Pharma deepens its direct bet on AI-designed cancer drugs.
DEEP DIVE
Value Add Research
Related Companies
Pathos AI FAQ
What is Pathos AI's valuation?
Pathos AI was last valued at $3B in its October 2026 Series E, according to SiliconANGLE (October 23, 2026).
How much has Pathos AI raised?
Pathos AI has raised at least $237M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $237M Series E in October 2026 at a $3B post-money valuation, reported by SiliconANGLE. Debt financing, tender offers and secondary sales are not counted.
Who invested in Pathos AI?
Lead investors in Pathos AI's sourced funding rounds include Bristol Myers Squibb. Per round: its October 2026 Series E was led by Bristol Myers Squibb.
Sources & methodologyshow
Where these figures come from
- SiliconANGLEmajor outlet2 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.